Cantor Fitzgerald Weighs in on Atyr PHARMA FY2024 Earnings

Atyr PHARMA INC (NASDAQ:ATYR) – Research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Atyr PHARMA in a report issued on Thursday, January 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will earn ($0.91) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.89) per share.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01).

Several other equities analysts also recently weighed in on ATYR. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Wells Fargo & Company assumed coverage on Atyr PHARMA in a research note on Friday, October 4th. They issued an “overweight” rating and a $17.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $19.25.

Atyr PHARMA Trading Down 5.6 %

Shares of NASDAQ:ATYR opened at $3.53 on Monday. The company’s 50 day moving average is $3.36. The company has a market cap of $296.32 million, a P/E ratio of -3.76 and a beta of 1.08. Atyr PHARMA has a 12-month low of $1.39 and a 12-month high of $4.22. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02.

Hedge Funds Weigh In On Atyr PHARMA

An institutional investor recently raised its position in Atyr PHARMA stock. JPMorgan Chase & Co. boosted its stake in Atyr PHARMA INC (NASDAQ:ATYR) by 52.0% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,440 shares of the company’s stock after purchasing an additional 10,754 shares during the quarter. JPMorgan Chase & Co.’s holdings in Atyr PHARMA were worth $55,000 as of its most recent SEC filing. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.